WallStSmart
PHXM

PHAXIAM Therapeutics S.A.

NASDAQ: PHXM · HEALTHCARE · BIOTECHNOLOGY

$3.10
+0.00% today

Updated 2026-05-01

Market cap
$28.90M
P/E ratio
P/S ratio
EPS (TTM)
$-39.05
Dividend yield
52W range
$0 – $0
Volume

PHAXIAM Therapeutics S.A. (PHXM) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20102011201220132014201520162017201820192020202120222023
Revenue$1.84M$1.80M$4.37M$10.78M$19.72M$3.36M$5.28M$0.00$0.00$0.00
Revenue growth (YoY)-2.0%+142.5%+146.6%+83.0%-82.9%-100.0%-100.0%
Cost of revenue$286051.00$315867.00$312577.00$261160.00$4.37M$10.78M$19.72M$530000.00$797000.00$4.22M$4.99M$5.38M$2.91M$1.61M
Gross profit$-286000.00$-316000.00$-313000.00$-261000.00$-25.46M$-33.47M$1.07M$-4.99M$-5.38M$-2.91M$-1.61M
Gross margin-17.0%-14.5%0.0%0.0%0.0%-756.9%20.2%
R&D$3.76M$3.56M$1.62M$2.50M$2.24M$10.53M$19.53M$25.46M$33.47M$52.19M$53.27M$40.22M$15.91M$9.84M
SG&A$3.30M$3.55M$4.36M$7.62M$6.66M$8.79M$14.60M$17.16M$14.97M$15.10M$13.89M
Operating income$-6.48M$-6.71M$-6.97M$-7.08M$-8.95M$-18.43M$-26.21M$-30.89M$-43.62M$5.28M$-72.55M$-56.52M$-32.08M$-25.42M
Operating margin-379.3%-393.2%-204.8%-171.0%-132.9%-918.2%100.0%
EBITDA$-6.20M$-6.40M$-6.66M$-8.02M$-10.72M$-15.25M$-25.78M$-33.72M$-47.27M$5.28M$-67.94M$-47.45M$-22.69M$-23.81M
EBITDA margin-362.4%-445.0%-245.5%-141.5%-130.8%-1002.5%100.0%
EBIT$-6.48M$-6.71M$-6.95M$-8.28M$-10.97M$-15.54M$-26.21M$-34.25M$-38.21M$8.23M$-72.93M$-52.83M$-25.60M$-25.42M
Interest expense$68876.00$224622.00$9382.00$4656.00$6801.00$5000.00$4000.00$3.18M$9000.00$1.53M$5.35M$2.14M$1.36M$196000.00
Income tax
Effective tax rate0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Net income$-4.84M$-5.91M$-2.17M$-8.14M$-8.86M$-15.01M$-21.91M$-33.53M$-38.22M$-62.66M$-73.30M$-53.80M$-227000.00$-23.49M
Net income growth (YoY)-22.1%+63.2%-275.0%-8.8%-69.4%-46.0%-53.0%-14.0%-63.9%-17.0%+26.6%+99.6%-10247.1%
Profit margin-118.2%-452.0%-202.8%-139.3%-111.1%-996.7%-1186.0%